Results 211 to 220 of about 172,168 (267)
Some of the next articles are maybe not open access.

Biology of BCR-ABL

Blood Reviews, 1999
gene on chromosome 9 is the humanhomologue of a gene originally identified in a murineoncogenic virus, the Abelson murine leukaemia virus(A-MuLV). This retrovirus was isolated from a pred-nisolone treated mouse which developed lymphomafollowing innoculation with Moloney murineleukaemia virus (M-MuLV).
R, Chopra, Q Q, Pu, A G, Elefanty
openaire   +2 more sources

BCR/ABL and leukemia

Leukemia Research, 1996
This review focuses on the role of the chimeric BCR/ABL gene in leukemia development. First, we discuss and update knowledge regarding the molecular biology of BCR/ABL. We then review data regarding transforming activity of BCR/ABL. Third, we discuss the complex interactions between BCR/ABL and leukemia phenotype. We conclude with a brief discussion of
A, Butturini, R B, Arlinghaus, R P, Gale
openaire   +2 more sources

The BCR/ABL hybrid gene

Baillière's Clinical Haematology, 1987
A DNA region on chromosome 22, designated M-BCR, contains the chromosomal breakpoint of the Philadelphia (Ph) translocation in all Ph positive CML patients studied to date. M-BCR is part of a gene, BCR, oriented with its 5' end towards the centromere of chromosome 22. All of the CML DNAs analysed have a breakpoint within introns of the BCR gene.
J, Groffen, N, Heisterkamp
openaire   +2 more sources

Osteopontin is upregulated by BCR-ABL

Biochemical and Biophysical Research Communications, 2005
Chronic myelogenous leukemia (CML) is characterized by its hallmark oncogene BCR-ABL and the progression from a chronic phase toward an acute leukemia, with a differentiation arrest of the leukemic clone. In the present study, we conducted a microarray analysis using an inducible model of BCR-ABL expression based on the TET-OFF system, and we found ...
S, Flamant   +9 more
openaire   +2 more sources

The immunogenicity of Bcr-Abl–expressing dendritic cells is dependent on the Bcr-Abl kinase activity and dominated by Bcr-Abl–regulated antigens

Blood, 2007
In Ph+ chronic myeloid leukemia (CML), the constitutively active Bcr-Abl kinase leads to the up-regulation and activation of multiple genes, which may subsequently result in the expression of leukemia-associated antigens. In this study, we investigated the immunogenicity of Bcr-Abl–regulated antigens by stimulating CD8+ T lymphocytes with autologous ...
Florian, Scheich   +3 more
openaire   +2 more sources

The Immunogenicity of BCR/ABL+ Cells Is Dominated by BCR/ABL-Regulated Antigens and Is Impaired by the Inhibition of BCR/ABL Kinase Activity.

Blood, 2006
Abstract The inhibition of BCR/ABL kinase activity by imatinib mesylate (IM, STI571, Gleevec®) is the standard therapy for patients with Philadelphia chromosome+ (Ph+) chronic myeloid leukemia (CML). However, the long term treatment with IM or other BCR/ABL kinase inhibitors may be limited due to the development of resistant disease and ...
Florian Scheich   +2 more
openaire   +1 more source

Essential thrombocythemia with BCR/ABL rearrangement

Cancer Genetics and Cytogenetics, 1996
Essential thrombocythemia (ET) was diagnosed clinically in three patients Karyotypic analysis and reverse transcription polymerase chain reaction for the bcr-abl chimeric transcript showed that two were Philadelphia chromosome (Ph) positive, bcr-abl positive, whereas the third was Ph negative, bcr-abl positive.
Kwong, YL   +4 more
openaire   +4 more sources

Wrapping BCR-ABL: it's in the bag

Blood, 2010
Abstract Leukemia, with its origin in a specific genetic abnormality, will only arise if the cell properly folds and processes the oncogenic protein encoded by the mutant gene. In this issue of Blood, Tsukahara and Maru describe a set of proteins that control the processing of the nascent BCR-ABL oncoprotein, providing new avenues for ...
Junia V, Melo, Duncan R, Hewett
openaire   +2 more sources

Mechanisms of Transformation by the BCR/ABL Oncogene

International Journal of Hematology, 2001
The Philadelphia chromosome generates a chimeric oncogene in which the BCR and c-ABL genes are fused. The product of this oncogene, BCR/ABL, has elevated ABL tyrosine kinase activity, relocates to the cytoskeleton, and phosphorylates multiple cellular substrates.
M, Sattler, J D, Griffin
openaire   +2 more sources

Response: too much BCR-ABL to live on, but too little BCR-ABL to die on?

Blood, 2012
The mechanistic understanding of persistence of leukemic stem cells during tyrosine kinase inhibitor therapy is an important unmet prerequisite for targeting residual CML and eradicating the disease.
Andreas Burchert   +2 more
openaire   +1 more source

Home - About - Disclaimer - Privacy